Clinical trial
A Single Arm,Open-label, Study of Fruquintinib Combined With Sintilimab and Chemotherapy in Patients With Unresectable or Metastatic Advanced Wild-type Genotype Non-squamous Non-small Cell Lung Cancer
NCT04956146 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm,Open-label, Study of Fruquintinib Combined With Sintilimab and Chemotherapy in Patients With Unresectable or Metastatic Advanced Wild-type Genotype Non-squamous Non-small Cell Lung Cancer
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 2, 2022
- Completion date
- September 30, 2024
- Enrollment
- 46 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.